• Parkwalk invested in a GBP 1.5 million private funding round for Qkine.
• Qkine is a Cambridge biotechnology company spun out of the University of Cambridge.
• Business focuses on high-purity, animal-origin-free growth factors, cytokines, and complex proteins for stem cell research and cell therapy manufacturing.
• Proceeds to expand US presence, strengthen leadership, accelerate R&D, scale GMP and cell therapy-grade manufacturing, improve digital platforms.
• Round also included CPI Enterprises, EverQuest Capital Partners, EMV Capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Parkwalk Advisors Ltd published the original content used to generate this news brief on September 07, 2026, and is solely responsible for the information contained therein.